Matthias Zachert

Matthias Zachert is a German business executive who has served as the chairman of the board of management of the specialty chemicals company Lanxess since 2014. He is widely credited with orchestrating a significant strategic and financial turnaround of the company, focusing on portfolio optimization, debt reduction, and a shift towards more stable, growth-oriented segments. Prior to his tenure at Lanxess, Zachert held several senior financial positions at the pharmaceutical and chemicals giant Merck KGaA, including chief financial officer.

Early life and education

Born in 1966 in Darmstadt, a city in the state of Hesse in West Germany, he demonstrated an early aptitude for business and finance. He pursued his higher education at the prestigious University of Mannheim, renowned for its strong programs in economics and business administration. At the university, he studied business administration, laying the academic foundation for his future career in corporate finance and management within the German chemical industry. Following his graduation, he embarked on his professional journey, quickly establishing himself within the financial structures of major DAX-listed corporations.

Career at Merck KGaA

Zachert began his long association with the Merck KGaA group in 1995, joining its financial controlling department. His expertise and strategic acumen led to a rapid ascent through the company's ranks, holding various financial leadership roles across different divisions, including Merck Serono. A pivotal moment in his career came in 2007 when he was appointed to the executive board of Merck KGaA as its chief financial officer, succeeding Michael Becker. In this role, he was instrumental in managing the company's finances during major strategic moves, most notably the high-profile acquisition of the American life science company Millipore in 2010, a deal valued at approximately $7.2 billion. He served on the executive board alongside CEOs Karl-Ludwig Kley and later Stefan Oschmann, contributing to the group's global expansion before departing in 2011.

CEO of Lanxess

In April 2014, Zachert was appointed chairman of the board of management of Lanxess, a company spun off from Bayer in 2004, succeeding Axel C. Heitmann. He inherited a company struggling with high debt, cyclical volatility, and an unbalanced portfolio heavily exposed to the synthetic rubber market. His strategy, often termed the "Zachert course," involved a rigorous restructuring program including significant cost-cutting, the divestment of non-core assets like the Performance Polymers segment to Aramco, and a strategic pivot towards higher-margin specialty chemicals such as flame retardants, water treatment products, and agricultural chemicals. Under his leadership, Lanxess also made key acquisitions, including Chemtura in 2017 and parts of Solvay's phosphorus chemicals business, strengthening its position in additive markets. His tenure has been marked by a strengthened balance sheet, a renewed focus on sustainability and digitalization, and navigating challenges such as the COVID-19 pandemic and the 2022 Russian invasion of Ukraine.

Leadership style and business philosophy

Known for a hands-on, data-driven, and financially disciplined approach, his leadership style is characterized by clear communication of strategic goals and a relentless focus on operational efficiency and shareholder value. He emphasizes portfolio management, advocating for a corporate structure built on resilient, less-cyclical businesses with strong market positions. This philosophy was evident in the transformation of Lanxess from a commodity-driven entity to a more specialized player. He is a frequent speaker at industry forums like the World Economic Forum and is recognized for his candid assessments of market conditions and geopolitical risks affecting the global chemical industry. His leadership during corporate turnarounds has drawn comparisons to other restructuring-focused German executives.

Personal life

He maintains a relatively private personal life, with limited public details shared. He is married and has children. His interests outside of the corporate world are not extensively documented, though his professional dedication to the chemicals sector and corporate governance is well-established. He serves on the supervisory board of Fresenius SE & Co. KGaA, a leading healthcare group, and has been recognized by financial publications for his impact on Lanxess's performance and strategic direction.

Category:German businesspeople Category:1966 births Category:Living people Category:University of Mannheim alumni Category:People from Darmstadt